About CDK4
The CDK4 gene (Cyclin Dependent Kinase 4) on chromosome 12q14 Activating R24C and R24H mutations in exon 2 disrupt p16INK4a binding and confer hereditary melanoma susceptibility. Key targets include Exons 1–8 for comprehensive mutation screening.
Mutations: R24C, R24H | GC content: 57% | Target exons: Exons 1–8
CDK4 Primer Design Challenges
- R24 hotspot mutations: Codon 24 in exon 2 is the sole recurrent mutation site, requiring targeted amplicon covering the glycine-rich loop
- Moderately high GC (57%): Exon 2 surrounding R24 has>65% GC content requiring denaturant optimization
- p16-INK4a binding interface: The mutation hotspot lies in the CDK4-p16 interaction domain necessitating careful primer placement
Recommended Primer Design Parameters for CDK4
| Parameter | Standard Exons | Optimized Regions |
|---|---|---|
| Primer length | 20–22 nt | 22–25 nt |
| GC content | 45–55% | 50–60% |
| Tm | 58–62°C | 60–65°C |
| Amplicon size | 150–300 bp | 180–350 bp |
| Annealing temp | 58–60°C | 60–64°C (touchdown) |
| PCR additive | Standard | Optional 3–5% DMSO for problematic regions |
Recommended Primer Sequences for CDK4
| Target Region | Forward Primer (5′→3′) | Reverse Primer (5′→3′) | Amplicon |
|---|---|---|---|
| Exon 2 (R24 hotspot) | 5′-CCTCACTTCCCCACATCTGA-3′ | 5′-TGGGAAAGCTGCCTAAATCC-3′ | 162 bp |
| Exon 5 (kinase domain) | 5′-AGCTGGCACTCAGAGTTTGA-3′ | 5′-TGTCATGAACACTCTCCTGG-3′ | 188 bp |
Key SNPs to Avoid in Primer Binding Sites
When designing CDK4 primers, avoid these clinically significant variants:
- rs121913351 (R24C) — Exon 2 hereditary melanoma mutation
- rs121913352 (R24H) — Exon 2 melanoma predisposition variant
Clinical Validation Required
All CDK4 primers designed with VigyanLLM are for research use only. Clinical diagnostic applications require additional wet-lab validation, Sanger sequencing confirmation, and regulatory approval before patient use.
Design CDK4 Primers Now
Pre-configured with CDK4-specific parameters. Use our primer design, Tm calculator, and GC content tools for optimal results.